Drug intelligence / Profile preview

Matrix Bound Nanovesicles

Development stage: Preclinical
Lead developer: ECM Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical, Ophthalmic

Overview

MBV (Matrix Bound Nanovesicles) is a preclinical-stage biologic therapy being developed by ECM Therapeutics, based on technology from the Badylak Laboratory at the University of Pittsburgh. These nanovesicles are derived from the extracellular matrix (ECM) and are formulated as topical ophthalmic eye drops. MBV is designed to promote corneal healing and provide protection against environmental damage, with potential applications in post-procedural healing and dry eye disease. The mechanism involves leveraging the regenerative properties of ECM-associated signaling molecules to facilitate tissue repair and modulate the local microenvironment.

Other names: Matrix Bound Nanovesicles

Targets

NF-κB

Beyond the preview

Go deeper on Matrix Bound Nanovesicles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matrix Bound Nanovesicles.

Explore the full profile